Pulsed Field Ablation with the Pentaspline Catheter vs Radiofrequency Ablation for Recurrent Atrial Fibrillation Authors: Wenbo Cheng, Xue Chen, Shiyi Wang, Mu Qin, Zonghan Zhao Published: 2026 ABSTRACT BackgroundPulsed field ablation (PFA) is a non-thermal energy modality for catheter ablation. Although recent studies have demonstrated that PFA is noninferior to radiofrequency ablation (RFA) for the initial treatment of atrial fibrillation (AF), its comparative efficacy and safety in patients who had AF recurrence following the initial ablation procedure remain unknown.MethodsFrom July 1, 2024 to September 30, 2024, 223 consecutive patients who had AF recurrence following the initial ablation procedure were prospectively enrolled from 2 participating centres and underwent either PFA using the pentaspline catheter (PFA group, n = 77) or RFA (RFA group, n = 146), based on clinical judgment. The effectiveness endpoint was freedom from AF/atrial tachycardia (AT) recurrence at 12 months.ResultsAt 12 months, no significant difference was present in the rate of freedom from AF/AT recurrence between the PFA and RFA groups (71.4% vs 67.8%; log-rank P = 0.514; hazard ratio 0.85, 95% confidence interval 0.52-1.38). Similarly, the incidence of safety endpoints did not differ significantly between the 2 groups (2.6% vs 3.4%; P = 0.947).ConclusionsIn patients who had AF recurrence following the initial ablation procedure, PFA using a pentaspline catheter demonstrated comparable effectiveness and safety to RFA, with similar rates of freedom from AF/AT recurrence and adverse events at 12 months. Compared to antiarrhythmic drug (AAD) therapy, catheter ablation has been shown to significantly improve the rate of freedom from atrial fibrillation (AF) and enhance quality of life.1, 2, 3 However, among patients with persistent AF, approximately 50% experience AF recurrence after the initial ablation procedure.4, 5, 6 Recurrent AF often leads to repeat procedures. Notably, repeat ablation provides only a modest, incremental improvement, of approximately 10%, in long-term sinus rhythm maintenance, compared to the initial procedure.5 Pulsed field ablation (PFA) is a novel non-thermal energy modality that has been adopted widely in clinical practice due to its unique tissue selectivity mechanism.7 Currently, a large number of clinical studies support the safety and efficacy of PFA for AF treatment.8, 9, 10 The Randomized Controlled Trial for Pulsed Field Ablation versus Standard of Care Ablation for Paroxysmal Atrial Fibrillation (ADVENT) demonstrated that PFA was noninferior to conventional thermal ablation in both efficacy and safety for patients with paroxysmal AF.11 The Single Shot Pulmonary Vein Isolation: Comparison of Cryoballoon vs. Pulsed Field Ablation in Patients With Symptomatic Paroxysmal Atrial Fibrillation (SINGLE SHOT CHAMPION) study demonstrated that PFA was noninferior to cryoballoon ablation with respect to the incidence of a first recurrence of atrial tachyarrhythmia, as assessed by continuous rhythm monitoring.12 The Multinational Survey on the Safety of the Postapproval Clinical Use of Pulsed Field Ablation in 17,000+ Patients (MANIFEST-17K study) indicated that a significant advantage of PFA is its ability to avoid most of the collateral damage associated with traditional thermal ablation.13 However, whether these findings can be generalized to more complex cases—specifically, patients who had AF recurrence following the initial ablation procedure—is not known. Therefore, we conducted a prospective, multicentre study to compare the efficacy and safety of PFA using the pentaspline catheter vs radiofrequency ablation (RFA) in this patient population. Methods Study design This multicentre, prospective, nonrandomized study was conducted between July 1, 2024 and September 30, 2024. A total of 223 consecutive patients who had AF recurrence following an initial ablation procedure were enrolled from 2 Chinese hospitals. Patients underwent either PFA using the pentaspline catheter (PFA group) or RFA (RFA group), based on clinical judgment. AF recurrence was defined as any episode of AF lasting > 30 seconds detected after the 3-month blanking period following the initial ablation procedure. No evidence of typical or atypical atrial flutter was documented on pre-procedural electrocardiography or Holter monitoring in any of the patients who underwent repeat procedures. Therefore, all included patients with recurrence had isolated AF recurrence rather than AF combined with atrial flutter. All ablation procedures were performed by experienced electrophysiologists, and the operators in the PFA group had completed substantial prior training with the system used. Written informed consent was obtained from all enrolled patients. The study protocol was approved by the institutional review boards of the Ren Ji Hospital and the other participating hospital. The study flowchart is shown in Figure 1.Figure 1Study flowchart. HF, heart failure; PFA, pulsed field ablation; PVI, pulmonary vein isolation; RFA, radiofrequency ablation. Study flowchart. HF, heart failure; PFA, pulsed field ablation; PVI, pulmonary vein isolation; RFA, radiofrequency ablation. Study population Patients were eligible if they were aged 18-80 years, had symptomatic AF refractory to at least one antiarrhythmic medication, had undergone pulmonary vein isolation (PVI) alone as the first ablation procedure, and were undergoing a second ablation due to AF recurrence. The exclusion criteria were as follows: (i) congestive heart failure with New York Heart Association (NYHA) class III or IV symptoms despite optimal medical therapy, or left ventricular ejection fraction < 35%; (ii) history of severe valve disease and/or prosthetic valve replacement; (iii) left atrial diameter > 60 mm; (iv) severe congenital heart disease; (v) left atrial thrombus confirmed by preoperative esophageal ultrasound; (vi) contraindications to anticoagulation therapy; (vii) contraindications for cardiac catheterization; (viii) any cardiac surgery within the preceding 2 months; and (ix) life expectancy < 12 months. Ablation procedures Repeat PVI was performed in patients with pulmonary vein (PV) reconnection. For patients with durable isolation of all PVs, direct current cardioversion was performed. The procedural details of RFA and PFA for PVI at the 2 participating centres are provided in the Supplementary Appendix S1. Briefly, radiofrequency ablation procedures were performed with the irrigated contact force–sensing ablation catheter Thermocool SmartTouchTM ST/SF (Biosense Webster, Irvine, CA) and the CARTO platform (Biosense Webster) using 45-50W (15-20 mL/min saline perfusion) with an ablation index of 450-550. PFA procedures were performed with the FARAPULSE catheter (Boston Scientific) and based on the 5S study. Each PV was treated with a minimum of 8 energy applications at 2.0 kV, 4 in the basket configuration and 4 in the flower configuration. PFA is guided by intracardiac echocardiography. (For more details, see Supplemental Appendix S1.) For patients with paroxysmal AF, only PVI was performed, whereas for those with persistent AF, additional posterior wall ablation was conducted. In the PFA group, posterior wall ablation was achieved using the pentaspline catheter in its flower configuration, with the number of energy applications tailored to the anatomic size of the posterior wall and guided by an electroanatomic mapping system. Cavotricuspid isthmus ablation was performed if sustained atrial flutter developed spontaneously during the procedure; this was carried out using radiofrequency ablation in both groups. No burst pacing or active triggering maneuvers for flutters or non-PV triggers was performed. General anesthesia was administered for all PFA procedures, whereas RFA procedures were performed under local anesthesia. Comprehensive procedural details are provided in Supplemental Appendix S1. Study endpoint The effectiveness endpoint was freedom from documented AF/atrial tachycardia (AT) lasting more than 30 seconds (after 3-month blanking), at a minimum of 12 months of follow-up after a single ablation procedure without AADs. The safety endpoints were acute adverse events (< 7 days postprocedure) and chronic major adverse events (> 7 days postprocedure). Major adverse events included esophageal fistula, symptomatic pulmonary vein stenosis, acute heart failure, surgical drainage, stroke, coronary spasm, persistent phrenic nerve injury, and vascular complications requiring surgical intervention. Minor adverse events included pericardial effusion without intervention, pericarditis, air embolism, hemolysis, transient ischemic attack, transient phrenic nerve injury, vascular access complications, hematoma, arteriovenous fistula, pseudoaneurysm, deep vein thrombosis, and respiratory-related events. Hemolysis was defined as a haptoglobin level of ≤ 4 mg/dL. Follow-up The first 3 months after the procedure were designated as the blanking period, during which class I or III AADs were permitted. After the blanking period, AADs were discontinued in patients with no evidence of AF recurrence. Patients were followed for 12 months, with outpatient clinic visits scheduled at 3,6, 9, and 12 months after discharge. At each visit, all patients underwent a 12-lead surface electrocardiogram (ECG) and 24-hour Holter monitoring. Any symptoms suggestive of recurrence were promptly evaluated with an additional 12-lead ECG or 24-hour Holter monitoring. Recurrence was defined as any episode of atrial arrhythmia lasting longer than 30 seconds, as confirmed by electrocardiographic documentation (ECG or Holter monitor). Statistical analysis Continuous variables are presented as mean ± standard deviation, or median with interquartile range. Categorical variables are presented as number and percentage. Comparisons between groups for continuous variables were made using the Student t test or the Mann–Whitney U test. Categorical variables are compared using χ2 tests. The Kaplan–Meier method was used to estimate the freedom from AF/AT recurrence during the follow-up period, and groups were compared with the log-rank test. To identify independent predictors of AF recurrence, we used univariable and multivariable Cox proportional hazards regression models. Variables entered into the multivariable model included age and those with a P value < 0.20 in the univariable analysis (male, persistent AF, and coronary artery disease). Results are presented as hazard ratios with 95% confidence intervals. All statistical tests were 2-sided, and a P value of < 0.05 was considered statistically significant. All statistical analyses were performed using GraphPad Prism version 10.1 (GraphPad, La Jolla, CA) and Statistical Package for the Social Sciences (SPSS, version 27.0, IBM, Armonk, NY). Results Baseline characteristics From July 1, 2024 to September 30, 2024, a total of 223 patients who had AF recurrence following the initial ablation procedure (mean age, 66.2 ± 9.2 years; 69.1% male) were enrolled in this prospective study and underwent either PFA using the pentaspline catheter or RFA. Baseline characteristics are presented in Table 1. There were no statistically significant differences in baseline characteristics between the 2 groups (Table 1). A total of 3 patients in the PFA group and 6 patients in the RFA group were lost to follow-up (Fig. 1).Table 1Baseline characteristicsCharacteristicAll patients (n = 223)PFA group (n = 77)RFA group (n = 146)PAge, Y66.2 ± 9.266.7 ± 8.766.0 ± 9.50.597Male154 (69.1)48 (62.3)106 (72.6)0.115BMI, kg/m224.9 ± 3.524.8 ± 3.724.9 ± 3.40.771Persistent AF126 (56.5)42 (54.6)84 (57.5)0.669CHA2DS2-VASC score2.2 ± 1.32.2 ± 1.32.1 ± 1.30.719Comorbidity Hypertension116 (52.0)41 (53.3)75 (51.4)0.790 Diabetes mellitus30 (13.5)8 (10.4)22 (15.1)0.330 Stroke or TIA27 (12.1)8 (10.4)19 (13.0)0.568 Coronary artery disease27 (12.1)13 (16.9)14 (9.6)0.112 Heart failure27 (12.1)5 (6.5)22 (15.1)0.062Echocardiography parameters LAD, mm45.1 ± 6.545.2 ± 7.445.1 ± 6.10.863 LVEF, %60.4 ± 8.561.4 ± 6.759.8 ± 9.30.187Values are mean (± standard deviation) or n (%), unless otherwise indicated. AF, atrial fibrillation; BMI, body mass index; CHA2DS2-VASC, Congestive Heart Failure, Hypertension, Age ≥ 75 Years, Diabetes Mellitus, Stroke, Vascular Disease, Age 65 to 74 Years, Sex Category; LAD, left atrial diameter; LVEF, left ventricle ejection fraction; .PFA, pulsed field ablation; RFA, radiofrequency ablation; TIA, transient ischemic attack. Table 1Baseline characteristicsCharacteristicAll patients (n = 223)PFA group (n = 77)RFA group (n = 146)PAge, Y66.2 ± 9.266.7 ± 8.766.0 ± 9.50.597Male154 (69.1)48 (62.3)106 (72.6)0.115BMI, kg/m224.9 ± 3.524.8 ± 3.724.9 ± 3.40.771Persistent AF126 (56.5)42 (54.6)84 (57.5)0.669CHA2DS2-VASC score2.2 ± 1.32.2 ± 1.32.1 ± 1.30.719Comorbidity Hypertension116 (52.0)41 (53.3)75 (51.4)0.790 Diabetes mellitus30 (13.5)8 (10.4)22 (15.1)0.330 Stroke or TIA27 (12.1)8 (10.4)19 (13.0)0.568 Coronary artery disease27 (12.1)13 (16.9)14 (9.6)0.112 Heart failure27 (12.1)5 (6.5)22 (15.1)0.062Echocardiography parameters LAD, mm45.1 ± 6.545.2 ± 7.445.1 ± 6.10.863 LVEF, %60.4 ± 8.561.4 ± 6.759.8 ± 9.30.187Values are mean (± standard deviation) or n (%), unless otherwise indicated. AF, atrial fibrillation; BMI, body mass index; CHA2DS2-VASC, Congestive Heart Failure, Hypertension, Age ≥ 75 Years, Diabetes Mellitus, Stroke, Vascular Disease, Age 65 to 74 Years, Sex Category; LAD, left atrial diameter; LVEF, left ventricle ejection fraction; .PFA, pulsed field ablation; RFA, radiofrequency ablation; TIA, transient ischemic attack. Baseline characteristics Values are mean (± standard deviation) or n (%), unless otherwise indicated. AF, atrial fibrillation; BMI, body mass index; CHA2DS2-VASC, Congestive Heart Failure, Hypertension, Age ≥ 75 Years, Diabetes Mellitus, Stroke, Vascular Disease, Age 65 to 74 Years, Sex Category; LAD, left atrial diameter; LVEF, left ventricle ejection fraction; .PFA, pulsed field ablation; RFA, radiofrequency ablation; TIA, transient ischemic attack. Procedural data Procedural data are presented in Table 2. The initial ablation for all patients was a successful PVI performed using radiofrequency ablation. At the repeat procedure, the overall PV reconnection rate was 30.9% (276 of 892 PVs), with no significant difference between the PFA and RFA groups (34.1% vs 29.3%, respectively; P = 0.071). The distribution of patients based on the number of reconnected PVs is shown in Figure 2 and Supplemental Figure S1. Notably, 25.6% of patients had all PVs durably isolated, whereas 39.5%, 24.7%, 6.3%, and 4.0% had 1, 2, 3, or 4 reconnected PVs, respectively (see Supplemental Fig. S1). No significant differences in this distribution were observed between the PFA and RFA groups (all P > 0.05; Fig. 2).Table 2Procedural dataCharacteristicPFA group (n = 77)RFA group (n = 146)PPV reconnection60 (77.9)106 (72.6)0.387Number of PVs reconnected∗105 (34.1)171 (29.3)0.071Repeat PVI60 (77.9)106 (72.6)0.387Success rate of repeat PVI†60 (100.0)106 (100.0)1.000Total procedure time, min109.9 ± 28.0152.9 ± 33.2< 0.001Total fluoroscopic time, min5.2 ± 1.517.1 ± 3.3< 0.001Posterior wall ablation42 (54.6)84 (57.5)0.669CTI ablation7 (9.1)14 (9.6)0.904DCCV at the procedure end35 (45.5)66 (45.2)0.972Type of anesthesiaGeneral77 (100.0)0 (0.0)< 0.001Local0 (0.0)146 (100.0)< 0.001Values are mean (± standard deviation) or n (%), unless otherwise indicated.CTI, cavotricuspid isthmus; DCCV, direct current conversion.∗The number (n) of pulmonary veins (PVs) for pulsed field ablation (PFA) group and radiofrequency ablation (RFA) group was 308 and 584, respectively.†Repeat pulmonary vein isolation (PVI) was performed in 60 patients in the PFA group and 106 patients in the RFA group.Figure 2Percentage of reconnected pulmonary veins (PVs) during repeat ablation. PFA, pulsed field ablation; RFA, radiofrequency ablation. Table 2Procedural dataCharacteristicPFA group (n = 77)RFA group (n = 146)PPV reconnection60 (77.9)106 (72.6)0.387Number of PVs reconnected∗105 (34.1)171 (29.3)0.071Repeat PVI60 (77.9)106 (72.6)0.387Success rate of repeat PVI†60 (100.0)106 (100.0)1.000Total procedure time, min109.9 ± 28.0152.9 ± 33.2< 0.001Total fluoroscopic time, min5.2 ± 1.517.1 ± 3.3< 0.001Posterior wall ablation42 (54.6)84 (57.5)0.669CTI ablation7 (9.1)14 (9.6)0.904DCCV at the procedure end35 (45.5)66 (45.2)0.972Type of anesthesiaGeneral77 (100.0)0 (0.0)< 0.001Local0 (0.0)146 (100.0)< 0.001Values are mean (± standard deviation) or n (%), unless otherwise indicated.CTI, cavotricuspid isthmus; DCCV, direct current conversion.∗The number (n) of pulmonary veins (PVs) for pulsed field ablation (PFA) group and radiofrequency ablation (RFA) group was 308 and 584, respectively.†Repeat pulmonary vein isolation (PVI) was performed in 60 patients in the PFA group and 106 patients in the RFA group. Procedural data Values are mean (± standard deviation) or n (%), unless otherwise indicated. CTI, cavotricuspid isthmus; DCCV, direct current conversion. The number (n) of pulmonary veins (PVs) for pulsed field ablation (PFA) group and radiofrequency ablation (RFA) group was 308 and 584, respectively.†Repeat pulmonary vein isolation (PVI) was performed in 60 patients in the PFA group and 106 patients in the RFA group. Percentage of reconnected pulmonary veins (PVs) during repeat ablation. PFA, pulsed field ablation; RFA, radiofrequency ablation. Repeat PVI was achieved successfully in all patients with PV reconnection (Table 2). The total procedure time was significantly shorter in the PFA group than in the RFA group (109.9 ± 28.0 minutes vs 152.9 ± 33.2 minutes; P < 0.001). In contrast, the fluoroscopy time was shorter in the RFA group (5.2 ± 1.5 minutes vs 17.1 ± 3.3 minutes in the PFA group; P < 0.001). Posterior wall ablation was performed in 42 patients (54.6%) in the PFA group and 84 patients (57.5%) in the RFA group (P = 0.669). Cavotricuspid isthmus ablation was performed for sustained atrial flutter that developed in 7 patients (9.1%) in the PFA group and 14 patients (9.6%) in the RFA group. Direct current cardioversion was performed at the end of the procedure for 35 patients (45.5%) in the PFA group and 66 patients (45.2%) in the RFA group (P = 0.972). General anesthesia was used for all PFA procedures, whereas RFA procedures were performed under local anesthesia (Table 2). Study outcomes At the 12-month follow-up, no significant difference was present in the primary effectiveness endpoint—freedom from documented AF/AT recurrence lasting > 30 seconds after the 3-month blanking period without class I/III AADs—between the PFA group and the RFA group (71.4% vs 67.8%; log-rank P = 0.514; hazard ratio [HR] 0.85; 95% confidence interval [CI] 0.52-1.38; Fig. 3).Figure 3Kaplan–Meier curves of freedom from atrial fibrillation/ atrial tachycardia (AF/AT) recurrence. CI, confidence interval; HR, hazard ratio; PFA, pulsed field ablation; RFA, radiofrequency ablation. Kaplan–Meier curves of freedom from atrial fibrillation/ atrial tachycardia (AF/AT) recurrence. CI, confidence interval; HR, hazard ratio; PFA, pulsed field ablation; RFA, radiofrequency ablation. Similarly, no significant differences were present in the incidence of safety endpoints between the 2 groups (2.6% vs 2.7%; P > 0.999; Table 3). Periprocedural hemolysis occurred in 2 patients in the PFA group. The hemolytic events were mild and self-limited, requiring no clinical intervention and resolving spontaneously. Minor adverse events occurred in 4 patients in the RFA group, 3 of which were hematomas and 1 of which was a pericardial effusion that required no intervention. No major adverse events occurred in either the PFA group or the RFA group.Table 3Safety endpointsAdverse eventsPFA group (n = 77)RFA group (n = 146)Overall adverse events24Major adverse events Esophageal fistula00 Symptomatic PV stenosis00 Acute heart failure00 Surgical drainage00 Stroke00 Coronary spasm00 Phrenic nerve injury (persistent)00 Vascular complications requiring surgery00Minor adverse events Pericardial effusion without intervention01 Pericarditis00 Air embolism00 Hemolysis20 TIA00 Phrenic nerve injury00 Vascular access complications Hematoma03 AV fistula00 Pseudoaneurysm00 DVT00 Respiratory-related00AV, arteriovenous; DVT, deep vein thrombosis; PFA, pulsed field ablation; PV, pulmonary vein; RFA, radiofrequency ablation; TIA, transient ischemic attack. Table 3Safety endpointsAdverse eventsPFA group (n = 77)RFA group (n = 146)Overall adverse events24Major adverse events Esophageal fistula00 Symptomatic PV stenosis00 Acute heart failure00 Surgical drainage00 Stroke00 Coronary spasm00 Phrenic nerve injury (persistent)00 Vascular complications requiring surgery00Minor adverse events Pericardial effusion without intervention01 Pericarditis00 Air embolism00 Hemolysis20 TIA00 Phrenic nerve injury00 Vascular access complications Hematoma03 AV fistula00 Pseudoaneurysm00 DVT00 Respiratory-related00AV, arteriovenous; DVT, deep vein thrombosis; PFA, pulsed field ablation; PV, pulmonary vein; RFA, radiofrequency ablation; TIA, transient ischemic attack. Safety endpoints AV, arteriovenous; DVT, deep vein thrombosis; PFA, pulsed field ablation; PV, pulmonary vein; RFA, radiofrequency ablation; TIA, transient ischemic attack. Risk factor–associated AF and/or AT recurrence The results of the univariable and multivariable analyses are presented in Table 4. In the univariable analysis, age (HR, 0.98; 95% CI, 0.96-0.99; P = 0.049) was associated with AF and/or AT recurrence. Other factors were not statistically associated with AF and/or AT recurrence.Table 4Results of univariable and multivariable analysisCharacteristicUnivariableMultivariableHR (95% CI)PHR (95% CI)PAge0.98 (0.96∼0.99)0.0490.98 (0.96∼1.00)0.070Male0.70 (0.43∼1.13)0.1450.71 (0.44∼1.17)0.171BMI1.00 (0.93∼1.07)0.985Persistent AF1.58 (0.96∼2.61)0.0731.52 (0.93∼2.55)0.103CHA2DS2-VASC score0.95 (0.79∼1.15)0.620Comorbidities Hypertension1.35 (0.84∼2.17)0.221 Diabetes mellitus0.96 (0.47∼1.93)0.902 Stroke or TIA1.04 (0.51∼2.09)0.919 Coronary heart disease0.51 (0.21∼1.27)0.1480.56 (0.19∼1.25)0.207 Heart failure0.92 (0.44∼1.93)0.833Echocardiographic parameters LAD1.00 (0.97∼1.04)0.913 LVEF0.99 (0.97∼1.03)0.831AF, atrial fibrillation; BMI, body mass index; CHA2DS2-VASC, Congestive Heart Failure, Hypertension, Age ≥ 75 Years, Diabetes Mellitus, Stroke, Vascular Disease, Age 65 to 74 Years, Sex Category; CI, confidence interval; HR, hazard ratio; LAD, left atrial diameter; LVEF, left ventricle ejection fraction; TIA, transient ischemic attack. Table 4Results of univariable and multivariable analysisCharacteristicUnivariableMultivariableHR (95% CI)PHR (95% CI)PAge0.98 (0.96∼0.99)0.0490.98 (0.96∼1.00)0.070Male0.70 (0.43∼1.13)0.1450.71 (0.44∼1.17)0.171BMI1.00 (0.93∼1.07)0.985Persistent AF1.58 (0.96∼2.61)0.0731.52 (0.93∼2.55)0.103CHA2DS2-VASC score0.95 (0.79∼1.15)0.620Comorbidities Hypertension1.35 (0.84∼2.17)0.221 Diabetes mellitus0.96 (0.47∼1.93)0.902 Stroke or TIA1.04 (0.51∼2.09)0.919 Coronary heart disease0.51 (0.21∼1.27)0.1480.56 (0.19∼1.25)0.207 Heart failure0.92 (0.44∼1.93)0.833Echocardiographic parameters LAD1.00 (0.97∼1.04)0.913 LVEF0.99 (0.97∼1.03)0.831AF, atrial fibrillation; BMI, body mass index; CHA2DS2-VASC, Congestive Heart Failure, Hypertension, Age ≥ 75 Years, Diabetes Mellitus, Stroke, Vascular Disease, Age 65 to 74 Years, Sex Category; CI, confidence interval; HR, hazard ratio; LAD, left atrial diameter; LVEF, left ventricle ejection fraction; TIA, transient ischemic attack. Results of univariable and multivariable analysis AF, atrial fibrillation; BMI, body mass index; CHA2DS2-VASC, Congestive Heart Failure, Hypertension, Age ≥ 75 Years, Diabetes Mellitus, Stroke, Vascular Disease, Age 65 to 74 Years, Sex Category; CI, confidence interval; HR, hazard ratio; LAD, left atrial diameter; LVEF, left ventricle ejection fraction; TIA, transient ischemic attack. The multivariable analysis was adjusted for age and variables, with P < 0.20 on univariable analysis (male, persistent AF, and coronary heart disease). After multivariable adjustment, age was not significantly associated with AF and/or AT recurrence in the multivariable analysis (HR, 0.98; 95% CI, 0.96-1.00, P = 0.070). Male, persistent AF, and coronary artery disease also were not significantly associated with AF recurrence in the multivariable analysis (all P > 0.05; Table 4). Discussion Main findings In this prospective, multicentre study, we found the following: (i) no statistically significant difference was present in the rate of freedom from AF and/or AT recurrence between the PFA and RFA groups; and (ii) the incidence of adverse events was comparable between the 2 groups. These results indicate that PFA using the pentaspline catheter is an effective and safe treatment option for patients who had AF recurrence following the initial ablation procedure, with outcomes comparable to those achieved with RFA. Procedural factors influencing repeat ablation success PVI remains the cornerstone of AF ablation. In patients undergoing repeat ablation for recurrent AF, PV reconnection is a critical determinant of procedural success. Previous studies have shown that among patients undergoing a third or more ablation procedures, the PV reconnection rate exceeds 90%.14 In a study of patients who underwent repeat AF ablation, those with more PV reconnections showed better clinical outcomes than those with fewer.15 In our study, only 25.6% of patients who had AF recurrence following the initial ablation procedure had durable PV isolation, indicating that the mechanism of recurrence in the majority of cases remains related to the PVs. Previous studies have reported acute PVI success rates approaching 100% with PFA, with long-term maintenance of isolation exceeding 90%.9, 10,16, 17, 18 Similarly, in our study, all patients with PV reconnection underwent repeat PVI, which demonstrated that PFA was effective for repeat procedures. The durability of the posterior wall isolation is another important factor. Although the Effect of Catheter Ablation Using Pulmonary Vein Isolation With vs Without Posterior Left Atrial Wall Isolation on Atrial Arrhythmia Recurrence in Patients With Persistent Atrial Fibrillation (CAPLA trial) demonstrated that adjunctive posterior wall ablation did not significantly reduce atrial arrhythmia recurrence,4 the reconnection of a previously isolated posterior wall remains a crucial mechanism for recurrent AF. Previous studies have shown that the incidence of reconnection after posterior wall isolation using thermal energy can reach up to 85%.19,20 Whether this high reconnection rate contributes to an underestimation of the true impact of posterior wall isolation on arrhythmia recurrence remains speculative. Evidence comes from a chronic remapping study of patients who had AF recurrence following the initial ablation procedure, which reported a 100% rate of durable posterior wall isolation when PFA was used.21 However, these findings are derived from a small, nonrandomized study and require confirmation in larger prospective trials. The Multi-National Survey on the Methods, Efficacy, and Safety on the Post-Approval Clinical Use of Pulsed Field Ablation (MANIFEST-PF study) found that adjunctive posterior wall isolation in patients with persistent AF did not significantly improve the rate of AF recurrence, compared with PVI alone.22 A point to note is that the present study did not perform posterior wall isolation during the initial procedure, nor did it systematically evaluate the durability of posterior wall isolation during repeat ablation. Therefore, the potential role of PFA in improving posterior wall isolation durability, as suggested by previous reports, remains hypothetical and was not tested directly in our study. Efficacy and safety of PFA for recurrent AF Patients who had AF recurrence following the initial ablation procedure present greater procedural complexity than treatment-naive patients, which is characterized by more advanced atrial remodelling and complex substrates. Our study demonstrated that PFA significantly reduced total procedure time compared to RFA (109.9 ± 28.0 minutes vs 152.9 ± 33.2 minutes, P < 0.001). Despite the uniform use of general anesthesia in the PFA group, PFA still enhanced procedural efficiency. In addition, fluoroscopy time was significantly longer in the PFA group than in the RFA group (17.1 ± 3.3 minutes vs 5.2 ± 1.5 minutes, P < 0.001). Regarding effectiveness, the freedom from AF and/or AT recurrence was similar between the 2 groups, even though 56.5% of the patients had persistent AF. This finding is consistent with previous studies.13,23 The absence of high-density electroanatomic mapping in the PFA group may have influenced this outcome. In addition, the incidence of adverse events was similar between the 2 groups. Only 2 cases of procedure-related hemolysis occurred in the PFA group. These events likely were due to an excessive number of PFA applications. A study on hemolysis after PFA showed that more than 70 PFA applications were significantly associated with perioperative hemolysis.24 Our retrospective review found that although the number of applications for these 2 patients did not reach 70, these numbers (54 and 62, respectively) were much higher than those for other patients. This difference may explain the hemolysis in these 2 cases. Moreover, no major complications occurred in the PFA group. Although the safety advantage of PFA could not be demonstrated fully in this study—likely due to the relatively small sample size and the low baseline incidence of such events—a larger-scale study, such as the MANIFEST-17K study, has shown that PFA reduces serious complications.12 Limitations This study has several limitations. First, this was a nonrandomized controlled study in which patients underwent either PFA using the pentaspline catheter or RFA based on clinical judgment. Therefore, the study is susceptible to selection bias, and the level of evidence it provides is lower than that of a randomized controlled trial. In addition, the sample size is small and the follow-up period is short. Therefore, larger-scale randomized controlled trials are needed to draw definitive conclusions. Second, follow-up was based on 12-lead surface ECG and 24-hour Holter monitoring, which is less sensitive for detecting AF and/or AT recurrence compared with continuous invasive monitoring. In addition, in this study, age was significantly associated with AF and/or AT recurrence in the univariable analysis but was not an independent predictor after adjusting for male sex, persistent AF, and coronary artery disease. This finding suggests that the effect of age on AF and/or AT recurrence may be partially mediated by these factors or may be related to the limited sample size and insufficient statistical power. In addition, no significant difference in recurrence rate was observed between patients with paroxysmal and persistent AF in this study, which may be related to the small sample size and insufficient statistical power. Therefore, this finding should be interpreted with caution, and larger-scale studies are warranted to further validate the impact of AF type on postablation recurrence. In addition, no a priori power calculation was performed during the design phase of this study. Based on a post hoc analysis, the statistical power to detect the observed intergroup difference with the current sample size is low. Therefore, the results should be interpreted with caution, considering the potential risk of a false-negative outcome. Nevertheless, the effect trend observed in this study provides valuable data for estimating the sample size in future larger-scale, well-designed randomized controlled trials. In addition, the small sample size means that minor variations between groups can lead to substantial differences in the outcomes. In 25.6% of patients, the PVs were already isolated at the beginning of the procedure, which resulted in an even smaller cohort undergoing redo PVI. In addition, a point to note is that all included patients with recurrence had isolated AF recurrence rather than AF combined with atrial flutter, as no evidence of typical or atypical atrial flutter was documented on pre-procedural electrocardiography or Holter monitoring. Accordingly, our findings may not be directly generalizable to all patients undergoing repeat ablation. Finally, only one PFA device was used (the FARAPULSE system), which limits the generalizability of the findings. Conclusion In patients who had AF recurrence following the initial ablation procedure, PFA using a pentaspline catheter demonstrated comparable effectiveness and safety to RFA, with similar rates of freedom from AF and/or AT recurrence and adverse events at 12 months. Ethics Statement The study protocol was approved by the institutional review boards of the Ren Ji Hospital and other participating hospitals. The research reported in this paper adhered to the Declaration of Helsinki. Patient Consent The authors confirm that patient consent forms have been obtained for this article. Funding Sources This research was supported by Grants from the National Natural Science Foundation of China (81770324). Disclosures The authors have no conflicts of interest to disclose.